Cancer Therapy Co. Karyopharm Hits Ch. 11 With Merger Plan
Pharmaceutical company Karyopharm Therapeutics Inc. on Monday filed for Chapter 11 protection in a Texas bankruptcy court with $441.5 million in debt and a plan to merge with biotechnology firm Ayrmid...To view the full article, register now.
Already a subscriber? Click here to view full article